Reduction in HTLV-I proviral load and spontaneous lymphoproliferation in HTLV-I-associated myelopathy/tropical spastic paraparesis patients treated with humanized anti-Tac.
Human T-lymphotropic virus type I (HTLV-I)-associated myelopathy/tropical spastic paraparesis (HAM/TSP) is a neurological disease that results from an interaction of retroviral infection and immune activation. In this study, five doses (1 mg/kg) of humanized anti-Tac antibody were administered to 9 HAM/TSP patients at weeks 0, 2, 6, 10, and 14. Preliminary immunological studies on HAM/TSP patients treated with humanized anti-Tac indicate that there is a selective down-regulation of activated T cells and a decrease in the HTLV-I viral load in peripheral blood lymphocytes, most likely through the selective removal of HTLV-I-infected, activated CD4+ lymphocytes.
Lehky
T J
TJ
Neuroimmunology Branch, National Institute of Neurological Disorders and Stroke, National Institutes of Health, Bethesda, MD, USA.
Levin
M C
MC
Kubota
R
R
Bamford
R N
RN
Flerlage
A N
AN
Soldan
S S
SS
Leist
T P
TP
Xavier
A
A
White
J D
JD
Brown
M
M
Fleisher
T A
TA
Top
L E
LE
Light
S
S
McFarland
H F
HF
Waldmann
T A
TA
Jacobson
S
S
D000906:Antibodies / Q000627:therapeutic use*; D001773:Blood Cells / Q000473:pathology; D002455:Cell Division / Q000502:physiology; D015368:Human T-lymphotropic virus 1 / Q000302:isolation & purification*; D006801:Humans; D016130:Immunophenotyping; D016131:Lymphocyte Subsets / Q000473:pathology; D008214:Lymphocytes / Q000473:pathology; D015493:Paraparesis, Tropical Spastic / Q000097:blood / Q000628:therapy* / Q000821:virology*; D011533:Proviruses / Q000302:isolation & purification*; D015375:Receptors, Interleukin-2 / Q000276:immunology*; D016896:Treatment Outcome; D019562:Viral Load
D000906:Antibodies; D015375:Receptors, Interleukin-2